Characteristics of Mild Dengue Virus Infection in Thai Children by Yoon, In-Kyu et al.
University of Rhode Island
DigitalCommons@URI
Institute for Immunology and Informatics Faculty
Publications Institute for Immunology and Informatics (iCubed)
2013
Characteristics of Mild Dengue Virus Infection in
Thai Children
In-Kyu Yoon
Anon Srikiatkhachorn
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has
been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of
DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Yoon, In-Kyu et al. "Characteristics of Mild Dengue Virus Infection in Thai Children." Am J Trop Med Hyg. 2013 Dec;89(6):1081-7.
doi: 10.4269/ajtmh.13-0424.
Authors
In-Kyu Yoon, Anon Srikiatkhachorn, Laura Hermann, Darunee Buddhari, Thomas W. Scott, Richard G.
Jarman, Jared Aldstadt, Ananda Nisalak, Suwich Thammapalo, Piraya Bhoomiboonchoo, Mammen P.
Mammen, Sharone Green, Robert V. Gibbons, Timothy P. Endy, and Alan L. Rothman
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/4
YOON AND OTHERS         MILD DENGUE VIRUS INFECTION 
 
Characteristics of Mild Dengue Virus Infection in Thai Children 
 
In-Kyu Yoon, Anon Srikiatkhachorn, Laura Hermann, Darunee Buddhari, 
Thomas W. Scott, Richard G. Jarman, Jared Aldstadt, Ananda Nisalak,  
Suwich Thammapalo, Piraya Bhoomiboonchoo, Mammen P. Mammen, Sharone Green,  
Robert V. Gibbons, Timothy P. Endy, and Alan L. Rothman. 
 
Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, 
Thailand; University of Massachusetts Medical School, Worcester, Massachusetts; Department 
of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Entomology, 
University of California, Davis, Davis, California; Department of Geography, University at 
Buffalo, Buffalo, New York; Bureau of Epidemiology, Department of Medical Sciences, 
Ministry of Public Health, Nonthaburi, Thailand; Department of Infectious Diseases, State 
University of New York, Syracuse, Syracuse, New York; Institute for Immunology and 
Informatics, University of Rhode Island, Providence, Rhode Island; Fogarty International Center, 
National Institutes of Health, Bethesda, Maryland 
 
ABSTRACT 
 
A four-year longitudinal cohort and geographic cluster study in rural Thailand was 
conducted to characterize the clinical spectrum of dengue virus (DENV) infection. Symptomatic 
DENV infections in the cohort were detected by active school absence-based surveillance that 
triggered cluster investigations around ill cohort children. Data from 189 cohort children with 
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symptomatic DENV infection and 126 contact children in the clusters with DENV infection were 
analyzed. Of infected contacts, only 19% were asymptomatic; 81% were symptomatic, but only 
65.9% reported fever. Symptom-based case definitions were unreliable for diagnosis. 
Symptomatic infections in contacts were milder with lower DENV RNA levels than the cohort. 
Infections in contacts with fever history were more likely to have detectable DENV RNA than 
infections without fever history. Mild infections identified by cluster investigations account for a 
major proportion of all DENV infections. These findings are relevant for disease burden 
assessments, transmission modeling, and determination of vaccine impact. 
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INTRODUCTION 
 Dengue virus (DENV) causes more human morbidity and mortality globally than any 
other vector-borne viral disease. Each year, an estimated 390 million people are infected with 
DENV of which 96 million are clinically apparent.1 Most of the information about the clinical 
presentation of dengue illness comes from moderate to severe infections that prompt patients to 
seek medical care, providing the basis for both the 1997 and 2009 World Health Organization 
(WHO) guidelines for dengue diagnosis and management.2-9 The sensitivities and specificities of 
these clinical indicators in identifying dengue illness are not well established. In particular, 
clinically mild DENV infections have not been as well described; information that is available 
has been obtained from prospective cohort studies and not from cluster studies which can 
potentially detect milder illnesses than cohort studies as well as pre-symptomatic infections.10-15 
Symptomatic DENV infections can be difficult to distinguish from other febrile illnesses using 
clinical parameters, especially with mild illness and early in the course of infection.8, 16-18 A 
better understanding of the clinical and virological characteristics across a wider clinical range of 
DENV infection is important to more accurately assess the burden of DENV infections and 
potential for virus transmission, and to make informed assessments of patients suspected of 
having dengue illness. We, therefore, undertook a combined longitudinal cohort and geographic 
cluster study in rural Thailand to evaluate the full clinical spectrum of DENV infection, 
including mild infections detected by cluster investigations. Such mild infections have not been 
previously well studied.12, 19, 20 
 
METHODS 
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Ethics Statement. The study protocol was approved by the Institutional Review Boards 
of the Thai Ministry of Public Health (MOPH), Walter Reed Army Institute of Research 
(WRAIR), University of Massachusetts Medical School (UMMS), University of California, 
Davis (UCD), and San Diego State University (SDSU). Written informed consent was obtained 
from the parents of study subjects; assent was obtained from subjects older than seven years. 
 
Prospective Longitudinal Cohort and Geographic Cluster Study. The study was 
conducted at 11 primary schools and 32 associated villages in rural areas of Muang district, 
Kamphaeng Phet province in north-central Thailand. The methodology is described elsewhere.12, 
19
 From 2004 to 2007, a dynamic prospective longitudinal cohort of approximately 2,000 
primary school children aged 4--15 years was monitored by active school absence-based 
surveillance from June to November each year.19, 21 An acute blood sample was drawn from 
cohort children who were absent from school and reported a fever in the previous seven days or 
had a measured temperature ≥ 38ºC. A convalescent blood sample was drawn 14 days later. A 
questionnaire assessing 12 specific symptoms was administered during the acute and 
convalescent visits; these symptoms could have been present at any time from seven days prior 
to the acute illness visit up to the day of the convalescent visit. Acute blood samples were tested 
by semi-nested reverse transcriptase polymerase chain reaction (RT-PCR) for detection of 
DENV RNA as previously described.22, 23 Paired acute and convalescent blood samples were 
tested by an in-house DENV/Japanese encephalitis virus (JEV) IgM/IgG capture EIA. JEV, 
which is endemic in rural Thailand, was included to rule out cross-reactivity with DENV.24 
 Cohort children who were DENV PCR-positive from an acute blood sample collected 
within three days of illness onset served as an index case for a positive geographic cluster 
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investigation around the child’s house (although the “index” case may not have been the first 
infection in the cluster). Cohort children who were DENV PCR-negative from an acute blood 
sample served as an index case for a negative (or control) geographic cluster investigation. Ten 
to 25 children aged six months to 15 years living within 100 meters of the index case were 
enrolled in each cluster investigation regardless of presence or absence of symptoms. These 
contact children were evaluated on the day of enrollment (i.e., day 0), and 5, 10, and 15 days 
later by temperature measurement and administration of a symptom questionnaire similar to the 
cohort. Symptoms could have been present at any time from seven days before day 0 up to day 
15. Blood samples were collected on days 0 and 15 and tested by both DENV PCR and 
DENV/JEV IgM/IgG EIA. All DENV PCR-positive acute samples from index cases and contact 
children also underwent quantitative RT-PCR (qRT-PCR) assay to determine serum viral RNA 
load at the time of blood collection.25 
 Cohort children additionally underwent scheduled phlebotomy prior to the active 
surveillance season (i.e., May) and at the end of the surveillance season (i.e., December/January). 
Paired pre/post-surveillance season blood samples were tested by hemagglutination inhibition 
(HAI) assay for all four DENV serotypes and JEV.26 Samples with a four-fold rise in HAI titers 
were re-tested by serotype-specific plaque reduction neutralization tests (PRNT) for DENV and 
JEV to confirm DENV seroconversion.27 
 
Clinical and Serologic Classification. In cohort children, an acute symptomatic DENV 
infection was considered to have occurred if a febrile illness was associated with a positive 
DENV IgM EIA and/or PCR in the acute or convalescent blood sample. DENV IgM-positive 
cases were considered to be primary infection (i.e., first in that child) if the DENV IgM:IgG ratio 
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was ≥ 1.8, and secondary infection (i.e., second or more in that child) if the ratio was < 1.8.24 A 
cohort child was considered to have clinically “inapparent” DENV infection during a 
surveillance season if paired pre/post-season blood samples showed a four-fold rise in DENV 
HAI confirmed by PRNT, but no symptomatic DENV infection was identified during that 
period.27 
 For contacts in the geographic clusters, an acute DENV infection was considered to have 
occurred if the day 0 or day 15 blood sample was positive by DENV IgM/IgG EIA and/or PCR.  
These DENV-infected contacts could have either symptomatic infection (i.e., symptoms detected 
by questionnaire or fever by temperature measurement) or asymptomatic infection (i.e., no 
detected symptoms or fever). 
 For both cohort and contact subjects, symptomatic DENV infections that required 
hospitalization were classified as dengue fever (DF) or dengue hemorrhagic fever (DHF) 
according to the 1997 WHO case definitions.2 Symptomatic DENV infections that did not 
require hospitalization were considered as non-hospitalized symptomatic DENV infection. 
  
Statistical Analyses. SPSS for Windows version 19 and MedCalc version 12.4 software 
were used for analyses. Symptoms were compared between the various diagnostic groups using 
the chi-squared test or Fisher’s exact test for categorical variables or t-test for continuous 
variables. Variables significant in univariate analyses were subsequently entered in a logistic 
binary regression model to identify independent associations. A statistical level of p<0.05 was 
considered significant. 
 
RESULTS 
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Clinical and Virological Features of DENV Infection in the Longitudinal Cohort. 
There were 189 symptomatic DENV infections and 346 clinically inapparent DENV infections 
in the cohort. Twenty additional DENV infections were clinically “unclassified” because they 
had DENV HAI/PRNT seroconversion between pre-/post-season blood samples but with an 
acute febrile illness detected during active surveillance that did not have acute/convalescent 
blood samples collected.12 General characteristics of dengue EIA-positive cohort children are 
detailed in Table 1. By study design, all EIA-positive cohort children were symptomatic with a 
fever history. All four DENV serotypes were detected with a predominance of DENV-1 (46.9%) 
and DENV-4 (36.7%); secondary infection was much more frequent (93.1%) than primary 
infection. There were 40 hospitalized DENV infections (31 DF and 9 DHF) accounting for 21.2% 
of symptomatic DENV infections and 7.2% of all DENV infections (symptomatic plus 
inapparent/unclassified). By univariate analysis, a measured temperature ≥ 38.0°C, headache, 
anorexia, muscle/joint pain, rash, drowsiness, abdominal pain, diarrhea and bleeding were 
significantly more frequent in DENV-infected cohort children with fever history compared with 
non-DENV infected cohort children with fever history (Table 2). The two symptoms with the 
highest odds ratios in dengue versus non-dengue febrile illnesses, namely rash and bleeding, 
occurred infrequently (4.2% and 3.2% of symptomatic DENV infections, respectively). Cough 
and rhinorrhea were significantly more common in non-dengue illnesses than in dengue illnesses, 
but still occurred quite frequently with dengue (42.3% with cough and 23.8% with rhinorrhea in 
dengue). Logistic regression analysis showed that five clinical features (measured temperature ≥ 
38.0°C, anorexia, rash, drowsiness, and bleeding) were independently associated with dengue 
febrile illnesses while cough was associated with non-dengue illnesses (Table 2). No significant 
differences in symptoms were found between primary and secondary infection (data not shown). 
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 Fever history along with two or more symptoms from the 1997 WHO case definition for 
suspected DF (i.e., headache, muscle/joint pain, rash and bleeding) had moderate specificity for 
detecting symptomatic DENV infection (83.7%; 95% CI 82.2--85.2), but low sensitivity (27.5%; 
95% CI 21.3--34.5). The positive and negative predictive values for this symptom complex were 
11.5% (95% CI 8.7--14.8) and 93.7% (95% CI 92.7--94.7), respectively. These values were 
similar if symptoms from the 2009 WHO criteria for probable dengue illness were used (i.e., 
fever with two or more of nausea/vomiting, rash, muscle/joint pain, abdominal pain, drowsiness 
[used as a surrogate for lethargy] or bleeding). Specificity was 81.2% (95% CI 79.6--82.8), 
sensitivity was 32.3% (95% CI 25.7--39.4), positive predictive value was 11.7% (95% CI 9.1--
14.8), and negative predictive value was 94.0% (95% CI 92.9--95.0). 
 Some symptom combinations increased the likelihood of a cohort illness being due to 
DENV infection (e.g., anorexia + bleeding [OR 13.2; 95% CI 3.3--53.3] or rash + absence of 
cough [OR 8.99; 95% CI 3.1--25.3]). However, these symptom combinations were uncommon 
(<10% of symptomatic DENV infections).  Other symptom combinations including various 
combinations of headache, anorexia and measured temperature ≥ 38.0°C yielded moderate 
sensitivities but were common in non-dengue febrile illnesses as well (data not shown). 
 Drowsiness and bleeding history (e.g., bleeding gums, epistaxis, hematemesis, 
hematochezia or melena) were the only symptoms individually associated with disease severity. 
Both symptoms were more common in DHF compared to DF (OR 7.2, 95% CI 1.7--30.2 for 
drowsiness; OR 29.5, 95% CI 4.9--177.6 for bleeding) and in hospitalized compared to non-
hospitalized dengue illnesses (OR 5.0, 95% CI 2.3--10.5; and OR 8.2, 95% CI 1.4--46.3, 
respectively). 
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 The proportion of symptomatic DENV infections that were DENV PCR-positive varied 
with the duration between illness onset and acute blood collection. The PCR-positive rate among 
symptomatic DENV infections was over 80% when the acute blood sample was collected within 
three days of illness onset and decreased to 64% after the third day of illness. DENV PCR was 
positive in 143 (86%) of 166 DENV infections when the acute blood sample was DENV IgM-
negative, and in four (22%) of 18 symptomatic DENV infections when the acute blood sample 
was IgM-positive (Chi-squared, p<0.001). 
 
Clinical and Virological Features of DENV Infection in Geographic Clusters. In 50 
positive cluster investigations, 119 (14.8%) of 805 contact children had laboratory-confirmed 
acute DENV infection on day 0. An additional 10 contacts who had DENV infection based 
solely on day 15 PCR-positive results were not included in further analysis because no clinical 
information was available after day 15. In 53 negative clusters, seven (0.9%) of 794 contacts had 
acute DENV infection; an additional two contacts were PCR-positive on day 15, but were not 
included in further analysis.12 General characteristics of DENV-infected contacts in the 
geographic clusters are detailed in Table 1. All four DENV serotypes were recovered with the 
same two serotypes predominating as in the cohort: DENV-1 (51.1%) and DENV-4 (37.2%); 
secondary infection (81.7%) was more frequent than primary infection but slightly less so than in 
the cohort. Asymptomatic DENV infections were detected in the clusters: 24 (19.0%) of 126 
DENV infections were asymptomatic while 102 (81.0%) were symptomatic. Of the symptomatic 
infections, 19 (18.6%) did not have fever history and reported no antipyretic use. Seven DENV-
infected contacts were hospitalized with DF or DHF (all from positive clusters) accounting for 
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7.0% of symptomatic infections and 5.6% of total DENV infections (symptomatic plus 
asymptomatic). 
Clinical symptoms in the 83 DENV-infected contacts who reported fever are detailed in 
Table 3. The comparison group includes DENV-negative contacts who reported fever in both 
positive and negative clusters; DENV-negative febrile contacts in positive versus negative 
clusters had no significant differences in symptoms (data not shown). Univariate analysis 
showed that symptoms of headache, anorexia, nausea/vomiting, muscle/joint pain, rash, 
abdominal pain and bleeding were more frequent in DENV-infected febrile contacts compared 
with DENV-negative febrile contacts. Logistic regression analysis showed that headache, 
muscle/joint pain and rash were independently associated with DENV infection (Table 3). Rash 
had the strongest association (AOR 7.6; 95% CI 3.0--19.8), but was present in only 15.7% of 
DENV-infected febrile contacts. Comparing primary with secondary symptomatic DENV 
infections, nausea and rash were more common in primary infection (AOR 18.2; 95% CI 1.8--
186.7, and AOR 13.9; 95% CI 2.0--97.5, respectively) whereas headache was less common in 
primary infection (AOR 0.2; 95% CI 0.01--0.3). Comparing symptomatic DENV-infected 
contacts with and without fever history, those without fever had fewer symptoms (not including 
fever) than those with fever (Table 4). Headache and nausea/vomiting were significantly more 
common in DENV-infected contacts with fever compared to symptomatic DENV-infected 
contacts without fever. None of the 19 symptomatic DENV-infected contacts without fever 
reported any symptoms of nausea/vomiting, muscle/joint pain, drowsiness, bleeding or diarrhea.  
Although we identified individual symptoms that distinguished dengue from non-dengue 
febrile illnesses in contacts, no combination of symptoms was able to distinguish between them. 
We were also unable to determine any symptom or symptom combination associated with 
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dengue severity, although our analysis was limited by the small number of contacts with severe 
disease. Symptoms from the 1997 WHO case definition for suspected DF had high specificity for 
detecting febrile symptomatic DENV infection (94.7%, CI 92.3--96.6), but low sensitivity 
(27.7%, CI 18.5--38.6). Positive and negative predictive values were 48.9% (95% CI 34.1--63.9) 
and 87.8% (95% CI 84.6--90.5), respectively. Values were similar using symptoms from the 
2009 WHO criteria for probable dengue illness with high specificity (91.7%, 95% CI 88.7--94.0) 
and low sensitivity (28.9%, 95% CI 19.5--39.9); positive and negative predictive values were 
38.7 (95% CI 26.6--51.9) and 87.6% (95% CI 84.3--90.4), respectively. 
 For those symptomatic DENV infections among contacts in which day 0 blood samples 
were collected within three days of illness onset, 18 (58.1%) of 31 blood samples were PCR-
positive. DENV PCR was positive in 33 (60.0%) of 55 DENV infections when the day 0 blood 
sample was DENV IgM-negative, but in only three (15.0%) of 20 DENV infections when the 
day 0 sample was IgM-positive (Chi-squared, p<0.001). 
 
Dengue Virus RNA Levels in Cohort and Contact Children. Comparing symptoms 
between DENV-infected cohort and contact children, cohort children were more likely to have a 
measured temperature ≥ 38°C, headache, muscle/joint pain, rash and drowsiness whereas 
contacts were more likely to have rhinorrhea and cough (Table 5). Per study design, all 50 index 
cases in positive clusters were DENV PCR-positive from their acute blood samples within three 
days of illness onset; three of these developed DHF. Among contacts, 40 PCR-positive DENV 
infections were detected from day 0 blood samples, of which 18 were collected within three days 
of illness onset. All 18 of these contacts were symptomatic with fever; none had DHF. 
Comparing the 47 non-DHF dengue index cases with these 18 DENV PCR-positive contacts, the 
 12
mean quantity of DENV RNA was 2.3 X 107 (range 9.9 X 102--2.14 X 108) copies/mL in index 
cases versus 7.1 X 106 (range 1.9 X 102--4.3 X 107) copies/mL in contacts (t-test, p = 0.03). 
Symptoms were not significantly different between these two groups (data not shown). 
 
DISCUSSION 
  Our combined cohort and cluster study demonstrates characteristics of DENV infection 
in children across a wide clinical spectrum of disease including mild infections identified from 
cluster investigations that have not been previously well described. Our results are applicable for 
disease burden assessments in endemic areas, virus transmission dynamics, clinical diagnosis, 
and disease pathophysiology. In our study population, mild dengue illness accounted for a 
majority of symptomatic DENV infections across all four serotypes. 
 Symptomatic DENV infections accounted for 81.0% of all DENV infections in contact 
children, but only 35.3% in cohort children. However, symptomatic infections seen in contacts 
were milder than in cohort children with fewer symptoms being reported. This may be explained 
by the difference in surveillance methods between the two groups. Contacts were evaluated for 
acute infection without regard to their clinical or functional status whereas cohort children were 
only evaluated for acute infection if they missed school due to a febrile illness. Hospitalized 
DENV infections accounted for a similar percentage of all DENV infections in both cohort and 
contact children (7.2% and 5.6%, respectively).  Since it is likely that hospitalized infections 
would be detected no matter what the surveillance method, the fact these percentages were 
similar suggests that most DENV infections were detected in both the cohort and clusters 
although the sensitivity for detecting symptoms varied with the surveillance method. These 
findings demonstrate that mildly symptomatic DENV infections, including afebrile illnesses and 
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mild febrile illnesses identified only by cluster investigations, constitute a previously 
uncharacterized spectrum of symptomatic disease. This highlights the importance of the 
surveillance method in defining illness for purposes such as disease burden assessments, 
transmission modeling, and determination of vaccine impact. 
Certain symptoms and symptom combinations were able to distinguish dengue from non-
dengue illnesses. However, these symptoms or symptom combinations occurred infrequently in 
DENV infections. Cough was able to distinguish non-dengue from dengue illnesses, but occurred 
too frequently in dengue illness to be used to exclude the diagnosis. Abdominal pain is a 
“warning sign” from the 2009 WHO dengue guidelines requiring close observation and medical 
intervention, although these “warning signs” have not been validated with respect to sensitivity, 
specificity, positive and negative predictive values. We noted no significant difference in 
abdominal pain between DENV-infected and uninfected symptomatic children in both cohort 
and contact children. Abdominal pain was, in fact, not infrequent in mild DENV infections. 
Symptoms from the 1997 and 2009 WHO case definitions for suspected or probable DF had 
moderate to high specificity and negative predictive value in distinguishing mild dengue illness 
from non-dengue illnesses, although the sensitivity and positive predictive value were low. In 
hyperendemic regions of Asia, these symptoms, therefore, may have some limited utility in 
excluding DENV infection. This finding would depend, however, on the identity and attack rates 
of other co-circulating pathogens such as influenza, chikungunya, or leptospirosis. Our study did 
not determine the specific etiologies of non-dengue illnesses. 
Considering only those symptomatic DENV infections not resulting in DHF, serum 
DENV RNA levels were significantly higher in DENV PCR-positive index cases than in PCR-
positive contacts from blood samples collected within three days of illness onset. Infections in 
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contacts were generally milder than in cohort children with fewer reported symptoms. In addition, 
DENV infections in contacts with fever history were more likely to be PCR-positive than those 
without fever history. The 19 DENV infections without fever history described in Table 4 were, 
for the most part, diagnosed by serology alone. These were, nevertheless, still probably acute 
infections since other symptoms besides fever were present and given that very few infections 
were comparably detected by serology in the negative clusters. Other studies have reported 
higher viral loads in DHF than in DF.28, 29 Our results suggest that serum viral load differs as 
well with more subtle clinical differences in symptomatic outpatient dengue. Differing viral 
loads in outpatients has implications for the differential ability of infected humans to transmit 
virus to mosquitoes. The severity of disease across the entire clinical spectrum should be 
factored into models that seek to predict patterns in DENV transmission. 
 Our study was limited to children in a dengue hyperendemic area of rural Thailand. We 
do not know, therefore, how well these findings apply to other regions with different dengue 
epidemiology or to adult populations. In addition, our study design did not allow us to conduct 
detailed analyses of changes in clinical features during the course of dengue illness as has been 
presented from a Nicaraguan longitudinal cohort,16 and our use of a symptom questionnaire at 
intervals separated by several days to two weeks may have led to some recall bias. We also 
cannot exclude the possibility of enrollment bias in the cluster investigations, for example, if 
healthy children were less inclined to participate in the study than sick children. Nevertheless, 
data obtained from DENV-infected children from our cluster investigations provides unique 
information on mild illness that has largely been unavailable previously.  
 By combining data from a longitudinal cohort with cluster investigations, we show a 
wide clinical spectrum of DENV infection in children that includes mild illnesses. While mildly 
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symptomatic DENV infection is difficult to distinguish from other febrile illnesses, it is quite 
common and these mild cases should, therefore, be considered when characterizing DENV 
infection and transmission. In addition, detection of DENV infection through cluster studies may 
be useful in addressing pathophysiological, immunologic and clinical aspects of disease 
progression from very early in the course of infection. 
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Description 
DENV-infected cohort 
children;  
N = 189 
DENV-infected contacts;  
N = 126* 
Median age (range) 9 (5-13) 9 (0-15) 
Sex   
     Male 92 (48.7) 68 (54.0) 
     Female 97 (51.3) 58 (46.0) 
Fever history 189 (100) 83 (65.9) 
Serological category   
     Primary 13 (6.9) 23 (18.3)** 
     Secondary 176 (93.1) 103 (81.7)** 
Dengue PCR positive 147 (77.8) 43 (34.1) 
Serotype   
     DENV-1 69 (46.9) 22 (51.1) 
     DENV-2 20 (13.6) 3 (7.0) 
     DENV-3 4 (2.7) 2 (4.7) 
     DENV-4 54 (36.7) 16 (37.2) 
 
Table 1: Characteristics of DENV-infected cohort and contact children; *includes 119 contacts 
from positive clusters and 7 from negative clusters; **variable timing of blood collection after 
infection in contacts makes this categorization less certain. 
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Symptom 
DENV-
infected with 
fever history 
(%); N = 189 
Non-DENV 
infected with 
fever history 
(%); N = 2449 
Odds ratio 
(95% CI) 
Adjusted odds 
ratio 
(95% CI) 
p-value for 
adjusted 
odds ratio 
Temp ≥ 38°C 125 (66.1) 1374 (56.1) 1.5 (1.1-2.1) 1.6 (1.1-2.2) 0.007 
Headache 160 (84.7) 1872 (76.4) 1.7 (1.1-2.6) - NS 
Anorexia 61 (32.3) 473 (19.3) 2.0 (1.4-2.8) 1.7 (1.2-2.5) 0.002 
Nausea/Vomiting 61 (32.3) 673 (27.5) 1.3 (0.9-1.7) - NS 
Muscle/Joint pain 49 (25.9) 446 (18.2) 1.6 (1.1-2.2) - NS 
Rash 8 (4.2) 19 (0.8) 5.7 (2.4-13.1) 4.3 (1.7-10.4) 0.002 
Rhinorrhea 58 (30.7) 1163 (47.5) 0.5 (0.4-0.7) - NS 
Cough 80 (42.3) 1637 (66.8) 0.4 (0.3-0.5) 0.4 (0.3-0.5) <0.001 
Drowsiness 45 (23.8) 278 (11.4) 2.4 (1.7-3.5) 2.0 (1.4-2.9) <0.001 
Abdominal pain 46 (24.3) 377 (15.4) 1.8 (1.3-2.5) - NS 
Diarrhea 14 (7.4) 92 (3.8) 2.1 (1.1-3.7) - NS 
Bleeding (any site) 6 (3.2) 15 (0.6) 5.3 (2.0-13.9) 4.5 (1.6-12.4) 0.004 
 
Table 2: Comparison of symptoms in DENV-infected and non-infected cohort children with 
fever history by univariate analysis (odds ratio) and binary logistic regression (adjusted odds 
ratio); NS = not significant 
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Symptom 
DENV-
infected with 
fever history 
(%); N = 83 
Non-DENV 
infected with 
fever history  
(%); N = 455 
Odds ratio 
(95% CI) 
Adjusted odds 
ratio 
(95% CI) 
p-value for 
adjusted odds 
ratio 
Temp ≥ 38°C 29 (34.9) 165 (36.3) 0.9 (0.6-1.5) - NS 
Headache 50 (60.2) 159 (34.9) 2.9 (1.8-4.6) 2.1 (1.3-3.5) 0.004 
Anorexia 20 (24.1) 52 (11.4) 2.5 (1.4-4.4) - NS 
Nausea/Vomiting 26 (31.3) 65 (14.3) 2.7 (1.6-4.7) - NS 
Muscle/Joint pain 13 (15.7) 18 (4.0) 4.5 (2.1-9.6) 2.8 (1.2-6.5) 0.01 
Rash 13 (15.7) 8 (1.8) 10.4 (4.2-25.9) 7.6 (3.0-19.8) <0.001 
Rhinorrhea 40 (48.2) 239 (52.5) 0.8 (0.5-1.3) - NS 
Cough 44 (53.0) 232 (51.0) 1.1 (0.7-1.7) - NS 
Drowsiness 9 (10.8) 25 (5.5) 2.1 (0.9-4.7) - NS 
Abdominal pain 17 (20.5) 42 (9.2) 2.5 (1.4-4.7) - NS 
Diarrhea 5 (6.0) 25 (5.5) 1.1 (0.4-3.0) - NS 
Bleeding (any site) 6 (7.2) 10 (2.2) 3.5 (1.2-9.8) - NS 
 
Table 3: Comparison of symptoms in DENV-infected and non-infected contacts with fever 
history by univariate analysis (odds ratio) and binary logistic regression (adjusted odds ratio); NS 
= not significant. 
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Symptom 
Symptomatic DENV-
infected with fever 
history 
(%); N = 83* 
Symptomatic DENV-
infected without fever 
history 
(%); N = 19* 
p-value 
Temp ≥ 38°C 29 (34.9) 0 (0.0) 0.001 
Headache 50 (60.2) 3 (15.8) <0.001 
Anorexia 20 (24.1) 2 (10.5) NS 
Nausea/Vomiting 26 (31.3) 0 (0.0) 0.003 
Muscle/Joint pain 13 (15.7) 0 (0.0) NS 
Rash 13 (15.7) 1 (5.3) NS 
Rhinorrhea 40 (48.2) 9 (47.4) NS 
Cough 44 (53.0) 8 (42.1) NS 
Drowsiness 9 (10.8) 0 (0.0) NS 
Abdominal pain 17 (20.5) 4 (21.1) NS 
Diarrhea 5 (6.0) 0 (0.0) NS 
Bleeding (any site) 6 (7.2) 0 (0.0) NS 
 
Table 4: Comparison of symptoms between DENV-infected contacts with and without fever 
history; *38/83 with fever history and 2/19 without fever history were DENV PCR-positive 
(Fisher’s exact, p=0.004); NS = not significant 
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Symptom 
Symptomatic DENV-
infected cohort 
children 
(%); N = 189 
Symptomatic 
DENV-infected 
contacts 
(%); N = 102 
p-value 
Fever history 189 (100.0) 83 (81.4) 0.0001 
Temp ≥ 38°C 125 (66.1) 29 (28.4) 0.0001 
Headache 160 (84.7) 53 (52.0) 0.0001 
Anorexia 61 (32.3) 22 (21.6) NS 
Nausea/Vomiting 61 (32.3) 26 (25.5) NS 
Muscle/Joint pain 49 (25.9) 13 (12.7) 0.01 
Rash 8 (4.2) 14 (13.7) 0.005 
Rhinorrhea 58 (30.7) 49 (48.0) 0.005 
Cough 80 (42.3) 52 (51.0) 0.0002 
Drowsiness 45 (23.8) 9 (8.8) 0.002 
Abdominal pain 46 (24.3) 21 (20.6) NS 
Diarrhea 14 (7.4) 5 (4.9) NS 
Bleeding (any site) 6 (3.2) 6 (5.9) NS 
 
Table 5: Comparison of symptoms between symptomatic DENV-infected cohort and contact 
children; NS = not significant 
 
